Shanghai Haohai Biological Technology , Ltd. PEG Ratio

Shanghai Haohai Biological Technology , Ltd. (6826.HK) currently reports a PEG ratio of -126.83. That is below the Healthcare sector average of 12.15. Use the charts on this page to explore Shanghai Haohai Biological Technology , Ltd.'s PEG ratio history and peer comparisons.

Shanghai Haohai Biological Technology , Ltd.'s PEG ratio of -126.83 is lower than the Healthcare sector average of 12.15. That is roughly 1143.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Shanghai Haohai Biological Technology , Ltd.'s market price to a fundamental measure such as earnings, sales, or book value. At -126.83, 6826.HK can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of -126.83, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 12.15. From there, open related valuation or income-statement pages for Shanghai Haohai Biological Technology , Ltd., and consider following 6826.HK for alerts when major investors trade the stock.

Shanghai Haohai Biological Technology , Ltd. is classified in the Healthcare sector. On PEG ratio, it currently shows -126.83 versus a sector average near 12.15. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6826.HK with unrelated industries.